We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the day. At the same time, the Dow lost 1.21%, and the tech-heavy Nasdaq lost 0.01%.
Prior to today's trading, shares of the biotechnology company had gained 4.85% outpaced the Medical sector's loss of 0.29% and the S&P 500's loss of 2.43%.
The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is predicted to post an EPS of -$0.24, indicating a 33.33% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.42 million, up 62.57% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and a revenue of $40.32 million, representing changes of +36.11% and -46.01%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.59% lower. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 165, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX - Free Report) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the day. At the same time, the Dow lost 1.21%, and the tech-heavy Nasdaq lost 0.01%.
Prior to today's trading, shares of the biotechnology company had gained 4.85% outpaced the Medical sector's loss of 0.29% and the S&P 500's loss of 2.43%.
The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is predicted to post an EPS of -$0.24, indicating a 33.33% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.42 million, up 62.57% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and a revenue of $40.32 million, representing changes of +36.11% and -46.01%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.59% lower. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 165, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.